May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
As HPV-vaccinated cohorts age into screening eligibility, researchers evaluated how cervical cancer screening intensity could be tailored by age at vaccination and vaccine type to balance benefits, harms,...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.
On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, based on...
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
